EU-RESPONSE (European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases)
EU-RESPONSE, a 5-year multi-national project, funded by the European Union’s Horizon 2020 research and innovation programme in order to design and run a new adaptive European platform trial on COVID-19 and emerging infectious diseases.
EU-RESPONSE will allow the European expansion of the DisCoVeRy study, a phase III, open-label, adaptive, randomized, controlled, multi-centre clinical trial designed to evaluate the safety and efficacy of medicinal products in hospitalized adult patients diagnosed with COVID-19. The DisCoVeRy trial was originally initiated in France as WHO Solidarity trial “add-on” study and thanks to EU-RESPONSE it will further expand to many other European countries.
Additionally, EU-RESPONSE will allow the building of a new multinational European Adaptive Platform Trial, based on existing initiatives, experiences and competencies – the EU-SolidAct. This will be a flexible platform, providing a modular trial network enabling most, if not all, European hospitals to participate at their preferred level of commitment. EU-SolidAct will aim to run repurposing trials, evaluating combination strategies as well as evaluating efficacy and safety of new compounds entering clinical development on COVID 19. Although in the short-term this project will focus on COVID-19, the mid-term/long-term objectives are to build a platform trial network on emerging infectious diseases in general. The project also includes a coordination module with the EU-funded RECOVER project, led by ECRIN, ensuring complementarity and cooperation across all large European COVID-19 Adaptive Platform trials, and their capacity to answer the needs of society through dialogue with the EMA, national competent authorities, HTAs and industry partners.
- 17-02-2021 - EU-RESPONSE launches website
- 18-09-2020 - EU-RESPONSE, a new tool in ECRIN’s arsenal to fight COVID-19